DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer.

On September 20, 2023, DermTech’s Compensation Committee approved the grant of an option to purchase 90,000 shares of the Company’s common stock pursuant to its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). The stock option has an exercise price of $1.69 per share and a 10-year term. Subject to Mr. Aguillard’s continued employment, twenty-five percent of the shares of the Company’s common stock exercisable pursuant to the option will vest on the first anniversary of the date of grant and the remaining seventy-five percent will vest in a series of thirty-six equal monthly installments.

In addition, Mr. Aguillard was granted restricted stock units representing the contingent right to receive 90,000 shares of the Company’s common stock under its 2022 Inducement Plan. The restricted stock units were approved by DermTech’s Compensation Committee, effective September 20, 2023, and were granted as inducements material to Mr. Aguillard’s acceptance of employment with DermTech in accordance with Nasdaq Listing Rule 5635(c)(4).

The 90,000 restricted stock units shall vest over 4 years as follows: (i) twenty-five percent of the restricted stock units will vest on September 20, 2024 and (ii) the remaining seventy-five percent of the restricted stock units will vest in equal quarterly installments until fully vested on September 20, 2027, subject to Mr. Aguillard’s continued employment with the Company on these vesting dates. The restricted stock units are subject to the terms and conditions of the 2022 Inducement Plan, and the terms and conditions of the equity award agreements covering the grants.

About DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers^TM. DermTech develops and markets products that facilitate the assessment of melanoma. For additional information, please visit DermTech.